Antiphospholipid antibodies in pregnancy: prevalence and clinical associations

Br J Obstet Gynaecol. 1993 Oct;100(10):909-13. doi: 10.1111/j.1471-0528.1993.tb15105.x.

Abstract

Objective: To determine prevalence, clinical association and predictive power of antiphospholipid antibodies in pregnancy.

Design: To test for the presence of anticardiolipin antibodies and lupus anticoagulant in order to confirm prevalence data which imply that each antibody has the same clinical significance. A detailed obstetric history and the outcome measures were obtained from each patient in the study.

Setting: National Women's Hospital, Auckland, New Zealand.

Subjects: Nine hundred and thirty-three consecutively booked pregnant women.

Main outcome measures: Prevalence of auto-antibodies; perinatal morbidity and mortality; incidence of pre-eclampsia, growth retardation and fetal distress.

Results: Nine women (1.0%) had anticardiolipin antibodies, 11 (1.2%) had lupus anticoagulant and two had both antibodies. The fetal mortality rate for women with antibodies was 167/1000. Pre-eclampsia occurred significantly more often in women with auto-antibodies.

Conclusion: The presence of antiphospholipid antibodies is frequently associated with adverse pregnancy outcome (9/18 pregnancies). High titre anticardiolipin antibodies carry a poor prognosis.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Anticardiolipin / analysis*
  • Autoantibodies / analysis
  • Female
  • Humans
  • Lupus Coagulation Inhibitor / immunology
  • Pregnancy / immunology*
  • Pregnancy Outcome
  • Sensitivity and Specificity

Substances

  • Antibodies, Anticardiolipin
  • Autoantibodies
  • Lupus Coagulation Inhibitor